{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["metformin"]],"indication":"advanced prostate cancer","name":"MANSMED","nct_id":"NCT03137186","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mansmed-nct03137186. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Mansmed","arms":[{"description":"Metformin will be added to standard of care","label":"Investigational arm","type":"ACTIVE_COMPARATOR"},{"description":"Patients will treated according to Standard of care only","label":"Control arm","type":"NO_INTERVENTION"}],"collaborators":[],"completion_date":{"date":"2020-01","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":120,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Metformin","otherNames":["Cidophage"],"type":"DRUG"}],"last_update":"2017-05-02","lead_sponsor":"Mansoura University","official_title":"Mansmed Trial : Repurposing Metformin as Anticancer Drug, RCT in Advanced Prostate Cancer","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2018-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"duration in months from beginning of treatment till development of CRPC","timeFrame":"2 years"}],"references":[{"citation":"Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, Kiss A, Fleshner NE, Pollak M, Klotz LH, Venkateswaran V. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis. 2012 Dec;15(4):346-52. doi: 10.1038/pcan.2012.16. Epub 2012 May 22.","pmid":"22614062","type":"RESULT"},{"citation":"Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011 Apr 6;9:33. doi: 10.1186/1741-7015-9-33.","pmid":"21470407","type":"RESULT"},{"citation":"Eriksson A, Attvall S, Bonnier M, Eriksson JW, Rosander B, Karlsson FA. Short-term effects of metformin in type 2 diabetes. Diabetes Obes Metab. 2007 Jul;9(4):483-9. doi: 10.1111/j.1463-1326.2006.00624.x.","pmid":"17587390","type":"RESULT"},{"citation":"Hamilton RJ. Metformin for castrate-resistant prostate cancer: learning more about an old dog's new tricks. Eur Urol. 2014 Sep;66(3):475-7; discussion 477-8. doi: 10.1016/j.eururo.2014.01.013. Epub 2014 Jan 23. No abstract available.","pmid":"24472709","type":"RESULT"},{"citation":"Hankinson SJ, Fam M, Patel NN. A review for clinicians: Prostate cancer and the antineoplastic properties of metformin. Urol Oncol. 2017 Jan;35(1):21-29. doi: 10.1016/j.urolonc.2016.10.009. Epub 2016 Nov 9.","pmid":"27836248","type":"RESULT"},{"citation":"Mayer MJ, Klotz LH, Venkateswaran V. Metformin and prostate cancer stem cells: a novel therapeutic target. Prostate Cancer Prostatic Dis. 2015 Dec;18(4):303-9. doi: 10.1038/pcan.2015.35. Epub 2015 Jul 28.","pmid":"26215782","type":"RESULT"},{"citation":"Ranasinghe WK, Sengupta S, Williams S, Chang M, Shulkes A, Bolton DM, Baldwin G, Patel O. The effects of nonspecific HIF1alpha inhibitors on development of castrate resistance and metastases in prostate cancer. Cancer Med. 2014 Apr;3(2):245-51. doi: 10.1002/cam4.189. Epub 2014 Jan 27.","pmid":"24464861","type":"RESULT"},{"citation":"Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bartschi D, Pollak M, Lui L, Endt K, Schiess R, Ruschoff JH, Cathomas R, Gillessen S. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur Urol. 2014 Sep;66(3):468-74. doi: 10.1016/j.eururo.2013.12.057. Epub 2014 Jan 4.","pmid":"24412228","type":"RESULT"},{"citation":"Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009 May;181(5):1998-2006; discussion 2007-8. doi: 10.1016/j.juro.2009.01.047. Epub 2009 Mar 14.","pmid":"19286225","type":"RESULT"},{"citation":"Song CW, Lee H, Dings RP, Williams B, Powers J, Santos TD, Choi BH, Park HJ. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep. 2012;2:362. doi: 10.1038/srep00362. Epub 2012 Apr 12.","pmid":"22500211","type":"RESULT"},{"citation":"Spratt DE, Zhang Z, Zelefsky MJ. Reply to Leah Bensimon, Samy Suissa, and Laurent Azoulay's letter to the editor re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16. Eur Urol. 2013 Aug;64(2):e29-30. doi: 10.1016/j.eururo.2013.04.015. Epub 2013 Apr 19. No abstract available.","pmid":"23619389","type":"RESULT"},{"citation":"Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.","pmid":"24321502","type":"RESULT"}],"start_date":{"date":"2017-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Repurposing Metformin as Anticancer Drug: in Advanced Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT03137186"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mansmed-nct03137186"}